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Abstract
Background: To determine whether chlamydia positivity among heterosexual men (MSW) and chlamydia and
gonorrhea positivity among men who have sex with men (MSM), are changing.
Methods: Computerized records for men attending a large sexual health clinic between 2002 and 2009 were
analyzed. Chlamydia and gonorrhea positivity were calculated and logistic regression used to assess changes over
time.
Results: 17769 MSW and 8328 MSM tested for chlamydia and 7133 MSM tested for gonorrhea. In MSW, 7.37%
(95% CI: 6.99-7.77) were chlamydia positive; the odds of chlamydia positivity increased by 4% per year (OR = 1.04;
95% CI: 1.01-1.07; p = 0.02) after main risk factors were adjusted for. In MSM, 3.70% (95% CI: 3.30-4.14) were
urethral chlamydia positive and 5.36% (95% CI: 4.82-5.96) were anal chlamydia positive; positivity could not be
shown to have changed over time. In MSM, 3.05% (95% CI: 2.63-3.53) tested anal gonorrhea positive and 1.83%
(95% CI: 1.53-2.18) tested pharyngeal gonorrhea positive. Univariate analysis found the odds of anal gonorrhea
positivity had decreased (OR = 0.93; 95% CI: 0.87-1.00; p = 0.05), but adjusting for main risk factors resulted in no
change. Urethral gonorrhea cases in MSM as a percentage of all MSM tested for gonorrhea also fell (p < 0.001).
Conclusions: These data suggest that chlamydia prevalence in MSW is rising and chlamydia and gonorrhea
prevalence among MSM is stable or declining. High STI testing rates among MSM in Australia may explain
differences in STI trends between MSM and MSW.
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Background
Chlamydia trachomatis (chlamydia) and Neisseria gonor-
rhea (gonorrhea) diagnosis rates have increased in Aus-
tralia over the last decade from 88.6 per 100,000
population in 2002 to 286.6 per 100,000 in 2009 for
chlamydia and from 30.7 per 100,000 in 2002 to 37.0
per 100,000in 2009 for gonorrhea [1]. While chlamydia
diagnoses have increased in both men and women,
increases in gonorrhea have been largely confined to
men who have sex with men (MSM) [2].
Surveillance data do not provide a valid measure of
either the prevalence or change in chlamydia in the gen-
eral population as over 80% of cases are asymptomatic
[3], and testing rates are low in Australia (less than 12%
of 15-24-year-old women and less than 5% of similarly
aged men) [4]. A recent analysis of a large sexual health
clinic in Australia, found that chlamydia positivity
increased by about 13% per year in women [5]. A simi-
lar analysis of chlamydia positivity among MSW in Aus-
tralia is yet to be published.
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among MSM have increased over the last decade in
Australia [6] and internationally [7-9]. In response, there
has been a push to increase STI testing with new testing
guidelines introduced in 2002 [10]. These guidelines
recommend that MSM should have annual chlamydia,
syphilis, gonorrhea and HIV tests and men at higher
risk of STIs (e.g. more than six partners in the last six
months) should be tested more frequently [10]. Since
the release of the guidelines, self reported STI testing
rates among MSM have increased [11]. In a survey of
MSM conducted annually in the State of Victoria, Aus-
tralia, the proportion of HIV negative MSM reporting
an annual STI test (excluding blood tests) has risen
from 46% in 2003 to 56% in 2009 (p < 0.01) [11]. It is
unclear what STI testing coverage is needed to achieve a
reduction in STI transmission. National STI surveillance
data are unable to answer this question because sexual
orientation is not routinely collected. Analyses of senti-
nel clinic data where sexual orientation is recorded
could help to monitor positivity over time.
In this paper we present the results of an analysis of
the computerized client records for men attending a
large urban sexual health clinic in Australia between
2002 and 2009. This analysis aimed to determine
whether chlamydia positivity has changed over time in
MSW. We also aimed to determine whether increased
STI testing was associated with changes in chlamydia or
gonorrhea positivity among MSM.
Methods
Study Population and Data Collection
This was a retrospective review of computerized records
between 1
st of July 2002 and 30
th of June 2009 at the
Melbourne Sexual Health Centre (MSHC), the principle
public STI clinic in Melbourne, the capital city of the
State of Victoria, Australia. The clinic conducts over
30,000 consultations annually and provides free HIV
and STI testing, using a walk in triage service for new
clients attending the centre. Individual computerized
records include basic demographic information such as
age and gender; behavioral information such as number
of male and female sexual partners in the last three and
twelve months, and condom use; and clinical informa-
tion including the presence or absence of genital symp-
toms, and whether or not the client reports contact with
chlamydia and/or gonorrhea. Symptoms can be chlamy-
dia or gonorrhea associated such as discharge or pelvic
pain, or unrelated symptoms such as genital ulcers or
genital lumps. The computerized record does not specify
the type of symptoms.
MSW are defined as men who have had sex with a
woman only in the previous 12 months and MSM are
defined as men who have had sex with another man in
the previous 12 months. Only clients attending MSHC
for the first time during the time period and were tested
for chlamydia if they were MSW or chlamydia and/or
g o n o r r h e ai ft h e yw e r eM S M ,w e r ei n c l u d e di nt h e
analysis.
MSHC policy throughout the time period the study,
was to offer first pass urine or urethral swabs for chla-
mydia to all MSW presenting to the clinic for the first
time and to test MSM in accordance with the STI
testing guidelines [10]. These guidelines recommend
pharyngeal swabs for gonorrhea, first pass urine for
chlamydia and anal swabs for both gonorrhea and chla-
mydia if they have had anal sex. Both policies remained
consistent and unchanged throughout the study period.
We also report the number of cases of urethral gonor-
rhea diagnosed at MSHC during the study period in
MSM. Screening for urethral gonorrhea in men without
symptoms is not recommended in Australia because
asymptomatic urethral gonorrhea is extremely rare [12].
In order to investigate trends in urethral gonorrhea in
MSM at MSHC, we calculated the proportion of ure-
thral infections among all MSM attending MSHC who
had had a test for gonorrhea at any site during the time
period.
I no r d e rt oe x a m i n ew h e t h e rc h a n g e so b s e r v e da t
MSHC are consistent with changes observed elsewhere
in Australia, we analyzed the number of chlamydia and
gonorrhea tests undertaken by the Victorian Infectious
Diseases Reference Laboratory (VIDRL) over the same
time interval. VIDRL is a public health laboratory that
provides STI testing services to two large general prac-
t i c ec l i n i c st h a th a v eah i g hc a s el o a do fM S M .T h e
number of anal and pharyngeal swabs tested and num-
ber of positive diagnoses was obtained and chlamydia
and gonorrhea positivity calculated to explore changes
over time. Men who tested more than once within any
two-week period were only included once in the analysis
and the sexual orientation of the patients were not
known. For the purpose of this additional analysis, we
assumed that any anal or pharyngeal swabs tested were
from MSM. We also obtained the number of gonorrhea
diagnoses notified to the Victorian Department of
Health during the study period. Gonorrhea diagnoses
are required by law to be notified.
This study was a clinical audit that included only de-
identified data. According to the national guidelines, an
ethics application is not required when there is no risk
involved [13].
Laboratory Methods
At MSHC, all specimens were analyzed for chlamydia
using BD ProbeTec Strand Displacement Amplification
NAA assay [5]. Anal and pharyngeal swabs for gonor-
rhea testing were directly plated at the time of specimen
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delivered to the on-site laboratory for culture.
At VIDRL, a number of NAA assays for detection of
both chlamydia and gonorrhea were used over the study
period. Both dry swabs (for PCR only) and swabs in
charcoal Amies transport medium (for culture and/or
PCR) were collected from anal and pharyngeal sites.
Initially, the Roche Cobas Amplicor
® CT/NG PCR
Assay was used to test total DNA extracts prepared
using A Roche™ MagNaPure or Corbett™ automated
DNA extractor. Given the specificity problem of the
Amplicor assay for the detection of gonorrhea [14], all
initial gonorrhea positive results were confirmed by a
second in-house PCR assay, the first to be used targeting
16S rRNA gene, the second the cppB gene, and the
third the polA pseudogene. Later, the Amplicor assay
was replaced by the Abbott™ m2000 TaqMan-based
PCR system which includes an automated total DNA
extraction step. For gonorrhea culture, swabs in charcoal
Amies transport medium were plated out on New York
City Agar and Chocolate or Horse-blood agar (depend-
ing on site) and incubated at 37°C in 5% CO2.T h e
plates were read daily for up to 4 days and isolates iden-
tified by conventional phenotypic methods.
Statistical Analyses
Chlamydia and gonorrhea positivity (the proportion of
men tested who were positive) estimates and 95% confi-
dence intervals were calculated using exact methods.
Logistic regression was used to assess associations
between chlamydia or gonorrhea positivity and year of
test adjusting for demographic, clinical, and sexual beha-
vioral risk factors. Contact with chlamydia or gonorrhea
and symptomatic presentations of either infection were
collapsed together for pragmatic purposes as demon-
strated previously [5]. Number of partners in the last 3
months was strongly correlated with the number of
partners in the last 12 months and condom use in the
last 3 months was strongly correlated with condom use
in the last 12 months. As a result, only one of the two
number of partners variables and one of the two con-
dom use variables was included in each regression
model; these were selected based on the likelihood ratio
test (p < 0.05) and varied between analyses. Chi-squared
analysis of trends was used to assess changes in risk fac-
tors over time.
Results
Heterosexual men (MSW)
There were 17769 chlamydia tests conducted among
MSW presenting for the first time during the time per-
iod. The median age of men tested for urethral chlamy-
dia was 29 years (range 13-85 years). Overall chlamydia
positivity for all MSW tested for chlamydia during the
time period was 7.37% (95% CI: 6.99-7.77) and increased
from 5.80% in 2002 to 8.02% in 2009 (Figure 1A).
Univariate analysis demonstrated a 3% greater odds of
chlamydia positivity from one year compared with the
previous year (OR = 1.03; 95% CI: 1.01-1.06; p = 0.03)
(Table 1). Multivariate analysis adjusting for age, num-
ber of sexual partners in the last 12 months, condom
use in the last 3 months, presence of symptoms and
contact with infection, found a 4% greater odds of chla-
mydia positivity from one year compared with the pre-
vious year (OR = 1.04; 95% CI: 1.01-1.07; p = 0.02).
The proportion of men reporting two or more sex
partners in the last 3 months increased from 41.8% in
2002 to 52.9% in 2009 (p < 0.01) and, in the last 12
months from 73.0% in 2002 to 80.0% in 2009 (p < 0.01),
Figure 1 Urethral and anal chlamydia positivity.C h a n g e si n
urethral chlamydia positivity over time in MSW and MSM (A) and in
anal chlamydia positivity over time in MSM (B) at the Melbourne
Sexual Health Centre (MSHC) and the Victorian Infectious Disease
Reference Laboratory (VIDRL). MSW = men who have sex with
women, MSM = men who have sex with men. NB: For 2002 and
2009, MSHC data are only available for a 6 month time period July-
Dec 2002 and Jan-June 2009.
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for condom use over 3 months and p = 0.40 for condom
use over 12 months). The proportion of men reporting
symptomatic presentation or contact with infection
decreased from 59.4% in 2002 to 55.9% in 2009 (p <
0.01).
Men who have sex with men (MSM)
There were 7977 tests for urethral and 6237 tests for
anal chlamydia (8328 clients) and 5833 anal and 6980
pharyngeal tests (7133 clients) for gonorrhea conducted
among MSM. The median age of men tested was 31
years (range 15-84 years), a similar profile to MSW
attending the clinic during the same time.
Chlamydia in MSM
Overall positivity for urethral chlamydia in all MSM
tested during the time period was 3.70% (95% CI: 3.30-
4.14) and for anal chlamydia was 5.36% (95% CI: 4.82-
5.96) and neither changed significantly between 2002
and 2009 (Figures 1A&B).
Univariate analysis found weak evidence to support a
decrease in the odds of urethral chlamydia positivity
(OR = 0.95; 95% CI: 0.90-1.01; p = 0.09) but no signifi-
cant change in the odds of men testing positive for anal
chlamydia over time (OR = 0.98; 95% CI: 0.93-1.03; p =
0.42) (Table 2). Multivariate analysis adjusting for age,
number of sexual partners in the last 3 months, condom
use in the last 12 months, presence of symptoms and
contact with infection, showed no significant change in
the odds of being positive for urethral chlamydia over
time (OR = 0.95; 95% CI: 0.88-1.01; p = 0.12). Multivari-
ate analysis adjusting for age, number of sexual partners
in the last 3 months, condom use in the last 12 months,
presence of symptoms and contact with infection, found
no change in the odds of anal chlamydia positivity from
one year compared to the previous year (OR = 0.99;
95% CI: 0.93-1.06; p = 0.76).
Among MSM testing for chlamydia, the proportion of
men reporting symptoms or contact with infection at
the time of testing decreased slightly from 39.1% in
2002 to 35.0% in 2009 (p < 0.01), but there was negligi-
ble change in the proportion reporting two or more sex-
ual partners (p = 0.40 for partners last 3 months and p
= 0.57 for partners in last 12 months) or condom use in
either the last 3 or 12 months (p = 0.23 for condom use
over 3 months and p = 0.95 for condom use over 12
months).
Over the same period there were 14083 anal swabs
submitted to the VIDRL laboratory of which 752 (5.3%;
95% CI: 4.98-5.73) were positive, a similar overall
Table 1 Chlamydia positivity and associations in men who have sex with women (MSW) attending MSHC 2002-2009
Variable Number tested Number positive (%) Crude OR (95% CI) Adjusted OR
b (95% CI)
All MSW 17769 1310 (7.37)
Year of test
a
1.03 (1.01-1.06) 1.04 (1.01-1.07)
Age group
< 25 4310 433 (10.05) 1.00 1.00
25-34 7908 632 (7.99) 0.78 (0.68-0.88) 0.79 (0.68-0.91)
> 35 5549 245 (4.42) 0.41 (0.35-0.49) 0.39 (0.32-0.46)
No. female sexual partners 12 mo
0-1 4263 172 (4.03) 1.00 1.00
> 1 12698 1089 (8.58) 2.23 (1.89-2.63) 2.11 (1.75-2.5)
Condom use 12 mo
always 2583 88 (3.41) 1.00
sometimes, usually, never 13883 1167 (8.41) 2.60 (2.09-3.24)
No. female sexual partners 3 mo
0-1 9499 565 (5.95) 1.00
> 1 7470 696 (9.32) 1.62 (1.45-1.82)
Condom use 3 mo
always 3024 110 (3.64) 1.00 1.00
sometimes, usually, never 12277 1117 (9.10) 2.65 (2.17-3.24) 2.78 (2.23-3.46)
Contact with infection or symptomatic presentation
No 6546 258 (3.94) 1.00 1.00
Yes 8650 937 (10.83) 2.96 (2.57-3.41) 3.34 (2.89-3.88)
a The odds ratio (OR) shows the association with chlamydia with each additional calendar year.
b Adjusted for age, number of sexual partners last 12 months, condom use last 3 months and contact history or symptomatic presentation.
OR = odds ratio, MSHC Melbourne Sexual Health Centre, mo = months
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Similarly, swabs tested for chlamydia at VIDRL showed
a significant decrease in the odds of positivity from one
year to the previous year (OR = 0.97; 95% CI: 0.93-0.99;
p = 0.05) (Additional file 1 Figure 1B). The number of
anal swabs submitted to the laboratory rose steadily
from 858 in 2002 to 2875 in 2009 (p < 0.01).
Gonorrhea in MSM
Overall positivity for anal gonorrhea for all MSM
included in the analysis was 3.05% (95% CI: 2.63-3.53)
and for pharyngeal samples was 1.83% (95% CI: 1.53-
2.18) (Figures 2A&B). Anal gonorrhea positivity
decreased over time from 3.44% in 2002 to 1.81% in
2009 but there was no change in pharyngeal gonorrhea
positivity over time.
Univariate analysis demonstrated a borderline signifi-
cant decline in the odds of men testing positive for anal
gonorrhea from one year to the previous year (OR =
0.93; 95% CI: 0.87-1.00; p = 0.05) but not for pharyngeal
gonorrhea (OR = 0.99; 95% CI: 0.91-1.07; p = 0.77)
(Table 3). Multivariate analysis adjusting for age, num-
ber of sexual partners in the last 3 months, condom use,
presence of symptoms and contact with infection, found
no change in the odds of being positive for either anal
or pharyngeal gonorrhea over time (OR = 0.99; 95% CI:
0.89-1.10; p = 0.27 and OR = 0.99; 95% CI: 0.91-1.11; p
= 0.79, respectively).
Among MSM testing for gonorrhea, the proportion of
men reporting two or more sex partners decreased from
66.60% to 63.5% for 3 months (p < 0.01) and from
87.6% to 83.4% for 12 months (p < 0.01), but there was
negligible change in condom use (p = 0.52). The pro-
portion of men reporting contact with infection or
symptoms decreased slightly from 49.0% in 2002 to
46.4% in 2008, before rising again in 2009 to 49.0% (p =
0.04).
Over the same period there were 14083 anal swabs
from MSM submitted to VIDRL for gonorrhea testing
by PCR and 10526 swabs submitted for culture of which
432 (3.07%; 95% CI: 2.79%-3.37%) and 361 (3.43%; 95%
CI: 3.09%-3.80%) were positive, respectively. Swabs
tested by PCR for gonorrhea showed a significant
decrease in the odds of positivity (OR = 0.86; 95% CI:
0.83-0.90; p < 0.01) (Additional file 1, Figure 2A).
Table 2 Chlamydia positivity and associations in men who have sex with men (MSM) attending MSHC 2002-2009
Urethral chlamydia Anal chlamydia
Number
tested
Number
positive (%)
Crude OR
(95% CI)
Adjusted OR
b
(95% CI)
Number
tested
Number
positive (%)
Crude OR
(95% CI)
Adjusted OR
b
(95% CI)
All MSM 7977 292 (3.70) 6237 334 (5.36)
Year of test
a
0.95 (0.90-1.01) 0.95 (0.88-1.01) 0.98(0.93-1.03) 0.99 (0.93-1.06)
Age group
< 25 1878 72 (3.83) 1.05 (0.78-1.42) 0.93 (0.62-1.38) 1565 82 (5.24) 1.18 (0.88-1.60) 1.30 (0.89-1.90)
25-34 3062 109 (3.56) 0.97 (0.74-1.27) 1.03 (0.74-1.44) 2453 153 (6.24) 1.42 (1.10-1.85) 1.53 (1.09-2.15)
> 35 3036 111 (3.66) 1.00 1.00 2218 99 (4.46) 1.00 1.00
No. male sexual partners 12 mo
0-1 1439 53 (3.68) 1.00 824 31 (3.76) 1.00 1.00
> 1 5672 211 (3.72) 1.01 (0.74-1.37) 4635 256 (5.52) 1.50 (1.02-2.19) 1.78 (1.06-3.00)
Condom use 12 mo
always 2615 78 (2.98) 1.00 1.00 2187 85 (3.89) 1.00
sometimes,
usually, never
3363 153 (3.98) 1.55 (1.17-2.05) 1.55 (1.14-2.11) 2963 204 (6.88) 1.83 (1.41-2.37)
No. male sexual partners 3 mo
0-1 2849 96 (3.37) 1.00 1.00 1970 86 (4.37) 1.00
> 1 4449 177 (3.98) 1.19 (0.92-1.53) 1.40 (1.00-1.95) 3661 213 (5.82) 1.35 (1.05-1.75)
Condom use 3 mo
always 2564 85 (3.32) 1.00 2205 93 (4.22) 1.00 1.00
sometimes,
usually, never
2920 135 (4.62) 1.41 (1.07-1.86) 2590 182 (7.03) 1.72 (1.33-2.22) 1.88 (1.40-2.52)
Contact with infection or symptomatic presentation
No 3169 61 (1.92) 1.00 1.00 2555 118 (4.62) 1.00 1.00
Yes 3008 174 (5.78) 3.13 (2.33-4.21) 2.79 (2.02-3.86) 2112 137 (6.49) 1.43 (1.11-1.85) 1.43 (1.08-1.89)
a The odds ratio (OR) shows the association with chlamydia with each additional calendar year.
b Adjusted for age, number of sexual partners last 12 months, condom use last 3 months and contact history or symptomatic presentation.
OR = odds ratio, MSHC Melbourne Sexual Health Centre, mo = months
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a significant decrease in the odds of positivity (OR =
0.73; 95% CI: 0.73-0.80; p < 0.01). The number of anal
swabs submitted for both PCR and culture rose between
two to three fold between 2002 and 2009 (Additional
file 1) (p < 0.01).
There were 2270 pharyngeal swabs submitted to
VIDRL for gonorrhea testing by PCR and 18,355 swabs
submitted for culture of which 89 (3.92%; 95% CI:
3.18%-4.82%) and 239 (1.30%; 95% CI: 1.14%-1.48%)
were positive respectively. Swabs tested by PCR for
gonorrhea showed a significant decrease in the odds of
being positive for pharyngeal gonorrhea (OR = 0.86;
95% CI 0.78-0.95; p < 0.01) (Additional file 1, Figure
2B). Similarly swabs tested by culture for gonorrhea
showed a significant decrease in the odds of positivity
(OR = 0.77; 95% CI 0.73-0.82; p < 0.01) (Additional file
1 Figure 2B).
There were 283 cases of urethral gonorrhea diagnosed
at MSHC during the study period. The odds of urethral
gonorrhea positivity decreased over the time period (OR
= 0.83; 95% CI: 0.78-0.88; p < 0.01) (Table 4).
Notifications per annum for gonorrhea in men
between 2002 and 2009 in Victoria were stable over
time (p = 0.63) (Figure 2A).
Discussion
We found that chlamydia positivity increased signifi-
cantly among MSW attending MSHC over the time per-
iod after adjustment for known risk factors. In contrast,
we found weak evidence to support a small decrease in
urethral chlamydia positivity and no change in anal
chlamydia positivity among MSM. We also found that
there was some evidence to suggest that anal gonorrhea
positivity among MSM declined during the same period.
This change may be explained by changes in risk beha-
viors. The percentage of men infected with urethral
gonorrhea also declined significantly at MSHC over the
same period. Data from the principle infectious diseases
laboratory for Melbourne, VIDRL, supported our clinic
findings showing significant declines in anal and pharyn-
geal gonorrhea positivity over time and a less marked,
but also significant, decline in anal chlamydia. It is
important to note that no adjustment for behavioral risk
was possible with the VIDRL data. Taking the MHSC,
VIDRL and Victorian gonorrhea notification data into
consideration, it appears that gonorrhea and chlamydia
rates in MSM are either stable or declining while chla-
mydia positivity among MSW appears to be rising.
A rise in chlamydia positivity in MSW is consistent
with our previously reported increase in chlamydia posi-
tivity in women attending MSHC. Community based
studies report similar prevalence estimates of 3 to
5% among young men and women alike in Australia
[15-18]. Other studies have also reported increasing
chlamydia positivity [5,6,19-24]. Surveillance data of the
proportion of chlamydia tests positive from Sweden,
Denmark, Ireland and the US [23-29] have also shown
increasing positivity. Sexual behavior data show that sex-
ual risk behavior is also changing with decreasing age at
first sex [30] and increasing number of annual sex part-
ners [31]. In this context, it appears that a true increase
in chlamydia infections among both women and MSW
appears likely, and that even the relatively high rates
of screening in the Scandinavian countries of about
25% per annum in women are insufficient to arrest this
rise [21].
While our analysis suggests that gonorrhea and chla-
mydia infection rates in MSM are stable or possibly
declining, the rates of syphilis and HIV in MSM have
Figure 2 Anal and pharyngeal gonorrhea positivity. Changes in
anal (A) and pharyngeal (B) gonorrhea positivity over time at both
Melbourne Sexual Health Centre (MSHC) and the Victorian Infectious
Disease Reference Laboratory (VIDRL; two types of sampling
methods; nucleic acid amplification assay and culture). The total
number of notified cases of gonorrhea in Victorian (VIC) men
between 2002 and 2009 are also indicated (A). NB: For 2002 and
2009, MSHC data are only available for a 6 month time period
July-Dec 2002 and Jan-June 2009.
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syphilis in Victoria compared with 391 in 2009 and
almost all cases occurred in MSM [32]. In 2002 there
were 165 newly diagnosed cases of HIV in men com-
pared with 238 in 2008 with over 80% of male cases in
MSM [2]. These increasing HIV and syphilis rates do
provide some evidence to suggest that sexual behavior in
the population may have changed and this is supported
by evidence from community based surveys of MSM
showing increases in sexual risk such as declining con-
dom use [11,33]. HIV and syphilis are different infections
from chlamydia and gonorrhea and likely to have differ-
ent transmission dynamics requiring different testing fre-
quencies. In this context, the declining gonorrhea and
chlamydia positivity observed in this study in combina-
tion with increasing sexual risk behavior over time, does
provide further evidence that gonorrhea and chlamydia
testing frequency among MSM may have reached a level
where we might start seeing control or even decreasing
community prevalence of these infections.
In MSM, very few studies have assessed the chlamydia
and gonorrhea positivity over time. Marcus et al.
reported positivity rates at several clinics in San Fran-
cisco from 2005 to 2008, and found no change in either
anal chlamydia or gonorrhea positivity [34]. However,
this study did not adjust for sexual risk factors or symp-
tomatic presentations. The authors attributed the stable
rates of positivity to a significant increase in STI testing
rates [34], supporting our hypothesis that increased test-
ing reduces positivity rates in MSM. In contrast to our
findings, an Australian MSM cohort study has reported
high incidences of urethral and anal chlamydia and
gonorrhea. But this study followed a single cohort of
MSM over time and did not include any new people
being tested [35].
There are a number of limitations in the analysis of
MSHC data. Firstly it is a retrospective analysis of
records from a sexual health clinic and may not be
representative of changes in prevalence in the popula-
tion. However, MSHC does a significant proportion of
testing for MSM and in 2008 for example, diagnosed
about 21% of Victorian gonorrhea cases [36]. Secondly,
we have analyzed the proportion of individuals who
tested positive each year rather than following a single
Table 3 Gonorrhea positivity and associations in men who have sex with men (MSM) attending MSHC 2002-2009
Anal Gonorrhea Pharyngeal Gonorrhea
Number
tested
Number
positive (%)
Crude OR
(95% CI)
Adjusted OR
b
(95% CI)
Number
tested
Number
positive (%)
Crude OR
(95% CI)
Adjusted OR
b
(95% CI)
All MSM 5833 178 (3.05) 6980 128 (1.83)
Year of test
a
0.93 (0.87-1.00) 0.95 (0.88-1.04) 0.99 (0.91-1.07) 1.01 (0.93-1.11)
Age group
< 25 1496 62 (4.14) 2.28 (1.44-3.60) 2.46 (1.54-3.94) 1735 47 (2.71) 1.00 2.68 (1.63-4.41)
25-34 2314 68 (2.94) 1.56 (0.99-2.45) 1.54 (0.96-2.46) 2677 50 (1.87) 0.68 (0.46-1.02) 1.70 (1.05-2.78)
> 35 2022 48 (2.37) 1.00 1.00 2567 31 (1.22) 0.44 (0.28-0.69) 1.00
No. male sexual partners 12 mo
0-1 784 11 (1.40) 1.00 1.00 965 10 (1.04) 1.00
> 1 4384 144 (3.28) 2.39 (1.29-4.43) 1.83 (0.91-3.64) 5314 107 (2.01) 1.96 (1.02-3.77)
Condom use 12 mo
always 2093 48 (2.29) 1.00
sometimes,
usually, never
2761 112 (4.06) 1.80 (1.28-2.54)
No. male sexual partners 3 mo
0-1 1861 36 (1.93) 1.00 2261 29 (1.28) 1.00 1.00
> 1 3465 126 (3.64) 1.91 (1.32-2.78) 4187 94 (2.25) 1.77 (1.16-2.69) 1.63 (1.05-2.54)
Condom use 3 mo
always 2107 54 (2.56) 1.00 1.00
sometimes,
usually, never
2414 101 (4.18) 1.66 (1.19-2.32) 1.64 (1.13-2.39)
Contact with infection or symptomatic presentation
No 2425 41 (1.69) 1.00 1.00 2876 29 (1.01) 1.00 1.00
Yes 1960 113 (5.77) 3.56 (2.48-5.11) 3.63 (2.45-5.38) 2468 85 (3.44) 3.50 (2.29-5.36) 3.69 (2.40-5.68)
a The odds ratio (OR) shows the association with chlamydia with each additional calendar year.
b Adjusted for age, number of sexual partners last 12 months, condom use last 3 months and contact history or symptomatic presentation.
OR = odds ratio, MSHC Melbourne Sexual Health Centre, mo = months
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Page 7 of 10cohort over time. However, cohort studies are expensive
and difficult to conduct. In the absence of cohort stu-
dies, analyses of medical records can be accepted for
investigating STI epidemiology over time. Finally,
because data was only available from July 2002 and the
analysis ended on the 30
th of June 2009, it is possible
that a seasonal variation may have influenced our analy-
sis. We therefore undertook a univariate analysis for
equal 12 month periods from 1
st of July 2002 onwards.
The results of this analysis were not different from the
analysis by year of diagnosis (data not shown).
Finally, we were unable to evaluate all possible factors
that may have affected the positivity over time. We did
not measure the clients’ sexual network characteristics
such as concurrency during this time period which may
be important in influencing an individual’s risk of infec-
tion [37]. We did however, measure other factors and
any changes were adjusted for in the analysis.
There were also a number of limitations for the data
from VIDRL. Firstly, these data do include some men
testing multiple times. However, the overall chlamydia
and gonorrhea positivity estimates were similar to those
at MSHC. Secondly, we have no data on the risk profile
of patients testing. However the decline in the propor-
tion positive, particularly for gonorrhea, was so striking
that it is unlikely that these factors or unmeasured con-
founding could disguise a true increase in the commu-
nity prevalence of either infection.
O u rd a t af r o mM S H Ch a v ean u m b e ro fs t r e n g t h s .
The analysis involved many men with either male or
female sexual partners tested over a number of years.
For chlamydia, the same laboratory and same diagnostic
testing methods were used throughout the study period.
For gonorrhea, both PCR and culture were used; how-
ever, only culture was used at MSHC during the study
period and while both PCR and culture were used at
VIDRL, the analysis was stratified by test type, to
account for any difference in trends that may have been
observed due to different test sensitivities. Furthermore,
the same testing criteria were in place during the study
period. The study is also strengthened by inclusion of
the VIDRL data. While these data do lack epidemiologi-
cal risk profiles, the specimens came from the same two
large MSM clinics in Melbourne over the entire study
period and give further support to the trends identified
in the MSHC data.
The clear difference in trends between MSW, where
chlamydia is rising, and MSM, where chlamydia and
gonorrhea are stable or possibly decreasing, suggests
that there may be different factors operating in these
two groups. Data from both MSW and MSM in Austra-
lia and internationally suggest their sexual risk profile is
changing with an increase in higher risk practices.
Further, in Australia there is evidence that community
antibiotic use is decreasing. Three Australian studies
have reported lower chlamydia rates among individuals
with recent antibiotic use [38-40]. Both changing sex-
ual behavior and antibiotic use should put upward
pressure on STI rates for MSW and MSM, yet this is
not observed in MSM. One possible reason for the dif-
ference in chlamydia trends between MSW and MSM
is the differential rates of STI testing. Only a small
minority (less than 12% of 15-24-year-old women and
less than 5% of 15-24-year-old) [4] of heterosexuals in
Australia have had a chlamydia test in the last year
w h i l ea b o u th a l fo fM S Mr e p o rt being tested [21]. This
raises the rather tantalizing possibility that we may
have reached the point where the reproductive number
for chlamydia and gonorrhea infection among MSM,
may be at the point of falling as a result of increased
testing.
Conclusions
Overall, it appears that chlamydia positivity is increasing
among MSW and chlamydia and gonorrhea positivity
among MSM is remaining stable, suggesting that the
epidemic of these two STIs may be equilibrating among
MSM but not in MSW. We therefore hypothesize that
increased testing could be having an impact on the
transmission of chlamydia and gonorrhea in the popula-
tion of MSM and that overall low rates of testing are
contributing to the ongoing rise of heterosexually trans-
mitted chlamydial infections in Australia.
Additional material
Additional file 1: Anal chlamydia and anal and pharyngeal
gonorrhea positivity for men who have sex with men at MSHC and
VIDRL by year.
Table 4 Urethral gonorrhea positivity in men who have
sex with men (MSM) attending MSHC 2002-2009
Year Number tested
a Number positive (%)
2002 632 19 (3.00)
2003 1104 84 (7.61)
2004 909 43 (4.73)
2005 931 32 (3.44)
2006 1007 46 (4.57)
2007 1055 21 (1.99)
2008 1286 28 (2.18)
2009 687 10 (1.46)
OR (95% CI)* 0.83 (0.78, 0.88)
p-value p < 0.01
a Number tested includes all MSM who were tested for gonorrhea at any site
NB: For 2002 and 2009, MSHC data are only available for a 6 month time
period July-Dec 2002 and Jan-June 2009. OR = odds ratio, CI = confidence
interval.
*Odds ratio for the association of gonorrhea positivity with year
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